This study examined the effectiveness, safety, and tolerability of Ruxolitinib (selective inhibitor of Janus kinase) cream in specific anatomical regions, particularly focusing on the head/neck lesions, in atopic dermatitis sufferers.

This post-hoc analysis utilized pooled data from the eight-week, vehicle-controlled period of the TRuE-AD1 and TRuE-AD2 studies. Researchers examined Eczema Area and Severity Index (EASI) responses in various anatomical regions in a pooled population of 1208 individuals, as well as among those with baseline involvement of the head/neck (n = 663). Furthermore, quality of life measures, itch severity, Investigator's Global Assessment (IGA), and tolerability of the cream at application sites were determined.

By week 2, Ruxolitinib cream illustrated remarkable improvements in EASI scores across all anatomical regions as opposed to the vehicle, with continued enhancements observed through week 8. A substantial proportion of patients with head/neck involvement who used Ruxolitinib cream attained pivotal reductions in itch severity, improvements in IGA, and enhanced quality of life when compared to those using the vehicle. The incidence of application site reactions with Ruxolitinib cream was low (<3%), even among those with head/neck involvement. At the site of application, Ruxolitinib cream was well-tolerated.

The findings of the study endorsed the effectiveness of Ruxolitinib cream for relieving atopic dermatitis across various anatomical regions, including the challenging head/neck area, which often poses challenges in management and considerably hampers the quality of life of the affected patients.